1. Dr. Reddy’s Launches Semaglutide Pill at ₹99 Starting Price

Company:Dr. Reddy’s LaboratoriesAnnouncement Date:June 2026What:Launch of affordable semaglutide pill for Type 2 diabetes and obesity managementKey Highlight:Most affordable semaglutide in India at ₹99 starting price, making GLP-1 therapy accessible to millionsImpact: Major price reduction in obesity/diabetes treatment market

2. Alkem Launches Pre-filled Syringe of Semaglutide at ₹350

Company:Alkem LaboratoriesAnnouncement Date:June 2026What:Launch of single-shot pre-filled syringe format for Type 2 diabetes and obesityKey Highlight:Following March launch of reusable pen, Alkem now introduces convenient pre-filled syringe at ₹350 starting priceImpact: Expands affordable GLP-1 therapy options in India

3. Lupin & Natco Receive US FDA Approval for Eribulin Mesylate Injection

Company:Lupin Ltd & Natco PharmaAnnouncement Date:June 2026What:US FDA approval for generic cancer drug Eribulin Mesylate injectionKey Highlight:Approved for breast cancer treatment, earning ₹400 crore revenue opportunity for LupinImpact: Strengthened portfolio in oncology generic drugs

4. Wockhardt’s Zaynich Novel Antibiotic Wins USFDA Approval

Company:Wockhardt LtdAnnouncement Date:June 2026What:Zaynich (Cefepime + Zidebactam) approved for complicated urinary tract infections including pyelonephritisKey Highlight:Novel antibiotic approved after 12-year effort, with blockbuster potential of $1.5–2 billionImpact: Major turnaround after years of net losses for Wockhardt

5. Aurobindo Pharma Telangana Facility Gets OAI Classification from FDA

Company:Aurobindo PharmaAnnouncement Date:June 2026What:Telangana (Borapatla) facility upgraded to OAI (Other than Acceptable) from FDAKey Highlight:Aurobindo inaugurated CDMO-arm biologics facility with 15,000-liter bioreactors, advanced downstream processing, fill-finish capabilitiesImpact: Enhanced biologics manufacturing capabilities for US market

International Announcements

1. AbbVie’s Rare Blood Cancer Drug Approved by FDA

Company:AbbVie Inc.Announcement Date:June 2026What:FDA approval for Baxfendy (rare blood cancer immunotherapy)Key Highlight:First drug in new class of cancer immunotherapies approved as initial treatment for advanced melanomaImpact: Positions AbbVie for new blockbuster run in cardio and cancer disease

2. Pfizer Launches Elranatamab in India for Multiple Myeloma

Company:Pfizer Inc.Announcement Date:June 2026What:Launch of Elranatamab (cancer bispecific therapy) in IndiaKey Highlight:Approved for patients with relapsed/refractory multiple myeloma who received at least 4 prior lines of therapyImpact: Expands treatment options for hard-to-treat blood cancer

3. Bristol Myers Squibb Drug Delays Myeloma Progression

Company:Bristol Myers SquibbAnnouncement Date:June 2026What:New drug delays myeloma progression in hard-to-treat patientsKey Highlight:Shows promising results in advanced melanoma and myeloma treatmentImpact: Significant advancement in blood cancer treatment pipeline

4. Lilly to Halve Planned €2.3 Billion Investment in Germany

Company:Eli Lilly & Co.Announcement Date:June 2026What:Reduced investment plan in Germany by 50%Key Highlight:Cuts €2.3 billion investment, focusing on strategic priorities in diabetes and obesity treatmentsImpact: Major shift in European manufacturing expansion strategy

5. Novo Nordisk’s Wegovy Approved for Teens in India

Company:Novo NordiskAnnouncement Date:June 2026What:FDA approval for Wegovy (weight-loss pill) for teenagersKey Highlight:Second country offering the pill after US, expanding accessibility for adolescent obesity treatmentImpact: Major milestone in weight management for teens